World Cholangiocarcinoma Day
Contribution and Sharing are powerful human elements in the cancer cure equation - this is my contribution.
Treat the Immune not the Cancer
A breakthrough by Dr Jim Allison Nobel Prize winner - we look into the Ipi /Nivo treatment, a two pronged attack on reactivating the T-Cell
What are Biomarkers
Biomarkers may be used to better understand some of the characteristics of your cancer. Getting tested for biomarkers helps your doctor decide what options are right for you.
PD-1 / PD-L1 is the Checkpoint Pathway
Learn how simple the PD-1 / PD-L1 Pathway is to understand - 4 short videos from easy to technical
A future look into Immuno-Oncology
what a line up! 2018 Nobel Prize winner James P. Allison, Philip D. Greenberg, M.D and Robert H. Vonderheide, Ph.D., and a fireside chat featured insights and opinions from Bristol-Myers Squibb's Vice President, Head of U.S. Oncology
1DH1 and TIBSOVO® (ivosidenib)
Phase 3 trial sees significant benefit as end point is achieved - The company plans to submit a supplemental new drug application for TIBSOVO® in previously treated IDH1 mutant cholangiocarcinoma by the end of 2019.
World Cholangiocarcinoma Day
Contribution and Sharing are powerful human elements in the cancer cure equation - this is my contribution.
Treat the Immune not the Cancer
A breakthrough by Dr Jim Allison Nobel Prize winner - we look into the Ipi /Nivo treatment, a two pronged attack on reactivating the T-Cell
What are Biomarkers
Biomarkers may be used to better understand some of the characteristics of your cancer. Getting tested for biomarkers helps your doctor decide what options are right for you.
PD-1 / PD-L1 is the Checkpoint Pathway
Learn how simple the PD-1 / PD-L1 Pathway is to understand - 4 short videos from easy to technical
A future look into Immuno-Oncology
what a line up! 2018 Nobel Prize winner James P. Allison, Philip D. Greenberg, M.D and Robert H. Vonderheide, Ph.D., and a fireside chat featured insights and opinions from Bristol-Myers Squibb's Vice President, Head of U.S. Oncology
1DH1 and TIBSOVO® (ivosidenib)
Phase 3 trial sees significant benefit as end point is achieved - The company plans to submit a supplemental new drug application for TIBSOVO® in previously treated IDH1 mutant cholangiocarcinoma by the end of 2019.
